MedKoo Cat#: 412939 | Name: Cipamfylline
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cipamfylline is a xanthine, a theophylline analogue, and is a potent and selective inhibitor of phosphodiesterase type 4 (PDE-4). Cipamfylline was tested in patients with a diagnosis of atopic dermatitis and in two human models of acute and chronic irritant contact dermatitis. The outcome of the study revealed that cipamfylline was more effective than vehicle in treating atopic dermatitis, but less effective than a group II steroid, hydrocortisone-17-butyrate both in the treatment of atopic dermatitis and irritant contact dermatitis. The absorption of cipamfylline and the subsequent systemic exposure might be the reason why further clinical studies with higher doses of cipamfylline have not been published.

Chemical Structure

Cipamfylline
Cipamfylline
CAS#132210-43-6

Theoretical Analysis

MedKoo Cat#: 412939

Name: Cipamfylline

CAS#: 132210-43-6

Chemical Formula: C13H17N5O2

Exact Mass: 275.1382

Molecular Weight: 275.31

Elemental Analysis: C, 56.71; H, 6.22; N, 25.44; O, 11.62

Price and Availability

Size Price Availability Quantity
5mg USD 685.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Cipamfylline; BRL61063; BRL-61063; BRL 61063
IUPAC/Chemical Name
1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro-
InChi Key
KSPYMJJKQMWWNB-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H17N5O2/c14-12-15-9-10(16-12)17(5-7-1-2-7)13(20)18(11(9)19)6-8-3-4-8/h7-8H,1-6H2,(H3,14,15,16)
SMILES Code
O=C(N1CC2CC2)N(CC3CC3)C4=C(NC(N)=N4)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 275.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J; Cipamyflline Study Group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol. 2002 Aug;147(2):299-307. doi: 10.1046/j.1365-2133.2002.04894.x. PMID: 12174103. 2: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. PMID: 12743628. 3: Kucharekova M, Hornix M, Ashikaga T, T'kint S, de Jongh GJ, Schalkwijk J, van de Kerkhof PC, van der Valk PG. The effect of the PDE-4 inhibitor (cipamfylline) in two human models of irritant contact dermatitis. Arch Dermatol Res. 2003 Apr;295(1):29-32. doi: 10.1007/s00403-003-0389-4. Epub 2003 Mar 4. PMID: 12709818. 4: Nankervis H, Thomas KS, Delamere FM, Barbarot S, Rogers NK, Williams HC. Scoping systematic review of treatments for eczema. Southampton (UK): NIHR Journals Library; 2016 May. PMID: 27280278. 5: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40. PMID: 12808477. 6: Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. doi: 10.2174/187152807780077318. PMID: 17352685. 7: Hiyama H, Arichika N, Okada M, Koyama N, Tahara T, Haruta J. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis. J Pharmacol Exp Ther. 2023 Jul;386(1):45-55. doi: 10.1124/jpet.123.001609. Epub 2023 Apr 11. PMID: 37041087. 8: Cramer RD, Jilek RJ, Andrews KM. Dbtop: topomer similarity searching of conventional structure databases. J Mol Graph Model. 2002 Jun;20(6):447-62. doi: 10.1016/s1093-3263(01)00146-2. PMID: 12071279. 9: Day JP, Lindsay B, Riddell T, Jiang Z, Allcock RW, Abraham A, Sookup S, Christian F, Bogum J, Martin EK, Rae RL, Anthony D, Rosair GM, Houslay DM, Huston E, Baillie GS, Klussmann E, Houslay MD, Adams DR. Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). J Med Chem. 2011 May 12;54(9):3331-47. doi: 10.1021/jm200070e. Epub 2011 Apr 13. PMID: 21456625. 10: Lehto M, Savinko T, Wolff H, Kvist PH, Kemp K, Lauerma A, Alenius H. A murine model of epicutaneous protein sensitization is useful to study efficacies of topical drugs in atopic dermatitis. Int Immunopharmacol. 2010 Apr;10(4):377-84. doi: 10.1016/j.intimp.2010.01.001. Epub 2010 Jan 13. PMID: 20074670.